Arman Qamar1, Sumeet A Khetarpal1, Amit V Khera1, Atif Qasim1, Daniel J Rader2, Muredach P Reilly2. 1. From the Department of Medicine, Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.Q., S.A.K., D.J.R., M.P.R.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston (A.V.K.); and Division of Cardiology, Department of Medicine, University of California at San Francisco (A.Q.). 2. From the Department of Medicine, Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.Q., S.A.K., D.J.R., M.P.R.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston (A.V.K.); and Division of Cardiology, Department of Medicine, University of California at San Francisco (A.Q.). muredach@mail.med.upenn.edu rader@mail.med.upenn.edu.
Abstract
OBJECTIVE: Triglyceride-rich lipoproteins have emerged as causal risk factors for developing coronary heart disease independent of low-density lipoprotein cholesterol levels. Apolipoprotein C-III (ApoC-III) modulates triglyceride-rich lipoprotein metabolism through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoproteins. Mutations causing loss-of-function of ApoC-III lower triglycerides and reduce coronary heart disease risk, suggestive of a causal role for ApoC-III. Little data exist about the relationship of ApoC-III, triglycerides, and atherosclerosis in patients with type 2 diabetes mellitus (T2DM). Here, we examined the relationships between plasma ApoC-III, triglycerides, and coronary artery calcification in patients with T2DM. APPROACH AND RESULTS: Plasma ApoC-III levels were measured in a cross-sectional study of 1422 subjects with T2DM but without clinically manifest coronary heart disease. ApoC-III levels were positively associated with total cholesterol (Spearman r=0.36), triglycerides (r=0.59), low-density lipoprotein cholesterol (r=0.16), fasting glucose (r=0.16), and glycosylated hemoglobin (r=0.12; P<0.0001 for all). In age, sex, and race-adjusted analysis, ApoC-III levels were positively associated with coronary artery calcification (Tobit regression ratio, 1.78; 95% confidence interval, 1.27-2.50 per SD increase in ApoC-III; P<0.001). As expected for an intermediate mediator, these findings were attenuated when adjusted for both triglycerides (Tobit regression ratio, 1.43; 95% confidence interval, 0.94-2.18; P=0.086) and separately for very low-density lipoprotein cholesterol (Tobit regression ratio, 1.14; 95% confidence interval, 0.75-1.71; P=0.53). CONCLUSIONS: In persons with T2DM, increased plasma ApoC-III is associated with higher triglycerides, less favorable cardiometabolic phenotypes, and higher coronary artery calcification, a measure of subclinical atherosclerosis. Therapeutic inhibition of ApoC-III may thus be a novel strategy for reducing plasma triglyceride-rich lipoproteins and cardiovascular risk in T2DM.
OBJECTIVE:Triglyceride-rich lipoproteins have emerged as causal risk factors for developing coronary heart disease independent of low-density lipoprotein cholesterol levels. Apolipoprotein C-III (ApoC-III) modulates triglyceride-rich lipoprotein metabolism through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoproteins. Mutations causing loss-of-function of ApoC-III lower triglycerides and reduce coronary heart disease risk, suggestive of a causal role for ApoC-III. Little data exist about the relationship of ApoC-III, triglycerides, and atherosclerosis in patients with type 2 diabetes mellitus (T2DM). Here, we examined the relationships between plasma ApoC-III, triglycerides, and coronary artery calcification in patients with T2DM. APPROACH AND RESULTS: Plasma ApoC-III levels were measured in a cross-sectional study of 1422 subjects with T2DM but without clinically manifest coronary heart disease. ApoC-III levels were positively associated with total cholesterol (Spearman r=0.36), triglycerides (r=0.59), low-density lipoprotein cholesterol (r=0.16), fasting glucose (r=0.16), and glycosylated hemoglobin (r=0.12; P<0.0001 for all). In age, sex, and race-adjusted analysis, ApoC-III levels were positively associated with coronary artery calcification (Tobit regression ratio, 1.78; 95% confidence interval, 1.27-2.50 per SD increase in ApoC-III; P<0.001). As expected for an intermediate mediator, these findings were attenuated when adjusted for both triglycerides (Tobit regression ratio, 1.43; 95% confidence interval, 0.94-2.18; P=0.086) and separately for very low-density lipoprotein cholesterol (Tobit regression ratio, 1.14; 95% confidence interval, 0.75-1.71; P=0.53). CONCLUSIONS: In persons with T2DM, increased plasma ApoC-III is associated with higher triglycerides, less favorable cardiometabolic phenotypes, and higher coronary artery calcification, a measure of subclinical atherosclerosis. Therapeutic inhibition of ApoC-III may thus be a novel strategy for reducing plasma triglyceride-rich lipoproteins and cardiovascular risk in T2DM.
Authors: Rishi Puri; Stephen J Nicholls; Mingyuan Shao; Yu Kataoka; Kiyoko Uno; Samir R Kapadia; E Murat Tuzcu; Steven E Nissen Journal: J Am Coll Cardiol Date: 2015-04-07 Impact factor: 24.094
Authors: L Masucci-Magoulas; I J Goldberg; C L Bisgaier; H Serajuddin; O L Francone; J L Breslow; A R Tall Journal: Science Date: 1997-01-17 Impact factor: 47.728
Authors: K Aalto-Setälä; E A Fisher; X Chen; T Chajek-Shaul; T Hayek; R Zechner; A Walsh; R Ramakrishnan; H N Ginsberg; J L Breslow Journal: J Clin Invest Date: 1992-11 Impact factor: 14.808
Authors: Sumeet A Khetarpal; Xuemei Zeng; John S Millar; Cecilia Vitali; Amritha Varshini Hanasoge Somasundara; Paolo Zanoni; James A Landro; Nicole Barucci; William J Zavadoski; Zhiyuan Sun; Hans de Haard; Ildikó V Toth; Gina M Peloso; Pradeep Natarajan; Marina Cuchel; Sissel Lund-Katz; Michael C Phillips; Alan R Tall; Sekar Kathiresan; Paul DaSilva-Jardine; Nathan A Yates; Daniel J Rader Journal: Nat Med Date: 2017-08-21 Impact factor: 53.440
Authors: Julian C van Capelleveen; Sophie J Bernelot Moens; Xiaohong Yang; John J P Kastelein; Nicholas J Wareham; Aeilko H Zwinderman; Erik S G Stroes; Joseph L Witztum; G Kees Hovingh; Kay-Tee Khaw; S Matthijs Boekholdt; Sotirios Tsimikas Journal: Arterioscler Thromb Vasc Biol Date: 2017-05-04 Impact factor: 8.311
Authors: Federico Oldoni; Kevin Bass; Julia Kozlitina; Hannah Hudson; Lisa M Shihanian; Viktoria Gusarova; Jonathan C Cohen; Helen H Hobbs Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958